Health & Education · Barcelona and New York

Daraxonrasib pill with chemotherapy shrinks pancreatic tumours in early trial

A once-daily pill given with chemotherapy made tumours undetectable on scans in about one in 12 patients in an early trial of 61 people with advanced disease.

AI text based on reports by The Independent, Η Ναυτεμπορική, ΣΚΑΪ and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Barcelona, New York · Spain, United States

Trial results

Daraxonrasib is a once-daily pill that targets a mutation in the KRAS gene, a mutation found in over nine in 10 pancreatic tumours. In the early phase I/II trial, it was combined with chemotherapy and given to 61 people recently diagnosed with advanced pancreatic cancer that had already spread to other parts of the body. Dr Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at a meeting of EORTC in Barcelona. Tumours shrank or disappeared in 60.7% of patients, and 8.2% reached a complete response, meaning the tumour could no longer be detected on scans. Tumours stopped growing in 90.2% of patients, a measure the trial calls the disease control rate, based on a typical follow-up of 18 months.

Tumour response with daraxonrasib plus chemotherapy%
Tumours shrank or disappeared
60.7 %
Complete response
8.2 %
Disease control rate
90.2 %

Data from the article text

Survival and duration

One year after treatment, 76.6% of patients were still alive, compared with around 40 to 45% of patients who received chemotherapy alone. On average, tumours took 12.8 months to return or begin growing again across the whole group. Some patients did not see their cancer come back during the study period. The drug drew attention in May 2026, when earlier findings suggested it nearly doubled survival compared with chemotherapy alone. Park said the results were extremely encouraging so far.

“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control”

Wungki Park

Expert caution

Doctors stress that the results are preliminary and should not be read as a cure. It remains unclear how long the disease can be kept under control, and longer studies are needed to establish whether any of these cancers can go into remission and for how long. Cancer Research UK described the findings as the biggest leap forward in decades for pancreatic cancer patients. Its Dr Sam Godfrey told BBC News that the results were incredibly exciting.

“What this new drug has done is it's found a way of drugging the undruggable.”

Sam Godfrey

Pancreatic cancer has the lowest survival rate of all common cancers in the UK, and most patients with advanced disease survive months rather than years. Chemotherapy can shrink tumours, but the cancer often grows back, so doctors hope the new treatment could give patients more time even if it cannot eliminate the disease.

Next steps

Daraxonrasib is already approved in the United States as a KRAS inhibitor treatment, although the pancreatic cancer results come from an early-stage study. Dozens of other cancers, including lung and ovarian cancer, can carry similar mutations, so the drug could in principle help other patients. Godfrey expressed hope that the early success seen in pancreatic cancer could later be extended to other cancers. Park noted that a higher response rate, deeper responses and a near doubling in the duration of disease control may eventually translate into longer survival, and researchers say longer studies are still needed to confirm how long these effects last.

Ask about this text

Sources and context

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar